Floatz logo

DEXAMETHASONE

Extraocular Extension Melanoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Extraocular Extension Melanoma cohort.

Asset / SponsorPhaseRating
Tyrosinase Peptide
National Cancer Institute (NCI)
Phase 3BB
FLUTICASONE
National Cancer Institute (NCI)
Phase 3BB
Sargramostim
National Cancer Institute (NCI)
Phase 3BB
FILGRASTIM
National Cancer Institute (NCI)
Phase 3BB
gp100 antigen
National Cancer Institute (NCI)
Phase 2BB

View all 25 →

Same molecule, other indications

DEXAMETHASONE is also rated in:

chemotherapy-induced toxicityDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →